SHANGHAI YIZHONG(SH:688091)2026-02-02 09:00Financial Projections - The total operating revenue for 2025 is projected to be RMB 317,076,818.03, representing an increase of 82.72% compared to RMB 173,532,721.07 in the previous year[5] - The net profit attributable to shareholders of the parent company is expected to reach RMB 64,131,993.35, a significant increase of 819.42% from RMB 6,975,282.60 in the prior year[5] - The net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses is projected at RMB 60,120,834.01, up 1,444.75% from RMB 3,891,951.20 year-on-year[5] - Basic earnings per share are expected to be RMB 0.31, a 933.33% increase from RMB 0.03 in the previous year[5] - The weighted average return on net assets is expected to increase to 4.46%, up by 3.97 percentage points from 0.49%[5] Assets and Equity - The company's total assets at the end of the reporting period are RMB 1,526,378,073.35, reflecting a growth of 5.41% from the beginning of the period[7] - The equity attributable to shareholders of the parent company is projected to be RMB 1,429,885,285.38, a growth of 1.77% from the beginning of the period[7] Research and Development - Research and development expenses for the year are estimated at RMB 85,060,300, an increase of approximately 128.63% compared to the previous year[8] - The core product, paclitaxel polymer micelles, was officially included in the national medical insurance directory in 2025, significantly boosting market access and patient numbers, thus driving revenue and profit growth[8] - The company is advancing the development of innovative drugs YXC-001 and YXC-002, achieving significant breakthroughs in their research processes[8]